Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations

Journal of Diabetes Science and Technology

Volumn 4, Issue 2, 2010, Pages 419-428

  Muchmore, Douglas B ^a   Vaughn, Daniel E ^a  

^a Halozyme Therapeutics Inc   (United States)

Author keywords

Diabetes; Glycemic control; Hyaluronidase; rHuPH20; Ultrafast insulin

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; HYALURONOGLUCOSAMINIDASE; INSULIN; INSULIN ASPART; INSULIN LISPRO; RECOMBINANT PROTEIN;

DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; EATING; GENETIC ENGINEERING; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE ABSORPTION; METABOLISM; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EATING; GENETIC ENGINEERING; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYALURONOGLUCOSAMINIDASE; HYPOGLYCEMIC AGENTS; INSULIN; INTESTINAL ABSORPTION; RECOMBINANT PROTEINS;

EID: 77955505940     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400223     Document Type: Review

References (50)

1. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31 Suppl 1:S12-54.
2. American college of endocrinology consensus statement on guidelines for glycemic control. Endocr Pract. 2002;8 Suppl 1:5-11.
3. International Diabetes Federation. Guideline for management of postmeal glucose. Brussels, Belgium: International Diabetes Federation; 2007.
4. Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, Gerich JE, Göke B. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280-5. (Pubitemid 46670411)
5. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-5. (Pubitemid 36929359)
6. Becker RH, Frick AD. Clinical pharmacokinetics and pharmaco-dynamics of insulin glulisine. Clin Pharmacokinet. 2008;47(1):7-20. (Pubitemid 350260885)
7. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmaco-dynamics of insulin aspart. Clin Pharmacokinet. 2001;40(9):641-59. (Pubitemid 32954988)
8. Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, Heise T. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005;28(5):1077-82. (Pubitemid 40616616)
9. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care. 1998;21(11):1910-4. (Pubitemid 28478292)
10. Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther. 2009;11(6):345-52.
11. Steiner S, Hompesch M, Pohl R, Simms P, Flacke F, Mohr T, Pfützner A, Heinemann L. A novel insulin formulation with a more rapid onset of action. Diabetologia. 2008;51(9):1602-6.
12. Rave KM, Nosek L, de la Peña A, Seger M, Ernest CS 2nd, Heinemann L, Batycky RP, Muchmore DB. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care. 2005;28(10):2400-5. (Pubitemid 41384284)
13. Heise T, Nosek L, Spitzer H, Heinemann L, Niemoller E, Frick AD, Becker RH. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007;9(5):746-53. (Pubitemid 47261856)
14. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22(9):1501-6. (Pubitemid 29418246)
15. Davies M. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord. 2004;28 Suppl 2:S14-22. (Pubitemid 39389602)
16. Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther. 2009;31(5):980-7.
17. Rave K, Potocka E, Boss AH, Marino M, Costello D, Chen R. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11(7):715-20.
18. Steiner S, Pfutzner A, Sethi B, Forst T, Klonoff D, Simms P, Pohl R, Flacke F. Insulin viaject and regular human insulin in patients with type 2 diabetes: efficacy and safety in an open-label multicenter clinical trial [abstract]. 44th Annual Meeting of the European Association for the Study of Diabetes; 2008 Sep 7-11; Rome, Italy.
19. Gnudi L, Lorber D, Rosenstock J, Howard C, Petrucci R, Shearer D, Bilheimer D, Chang PC, Kramer D, Richardson PC. Basal/bolus with prandial inhaled Technosphere insulin plus insulin glargine vs biaspart 70/30 insulin in type 2 diabetes inadequately controlled on insulin with/without oral agents [abstract]. Diabetologia. 2009;52 Suppl 1:S360.
20. Lorber D, Howard C, Ren H, Rossiter A, Boss A. Reduced incidence and frequency of hypoglycaemia in an integrated analysis of pooled data from clinical trials of subjects with type 2 diabetes using prandial inhaled Technosphere insulin [abstract]. Diabetologia. 2009;52 Suppl 1:S360.
21. Howard C, Ren H, Rossiter A, Boss A. Reduced incidence and frequency of hypoglycaemia in an integrated analysis of pooled data from clinical trials of subjects with type 1 diabetes using prandial inhaled Technosphere insulin [abstract]. Diabetologia. 2009;52 Suppl 1:S386-7.
22. Hylenex (hyaluronidase human injection)[product information]. Deerfield, IL: Baxter Healthcare Corporation; 2009.
23. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006;114(2):230-41. (Pubitemid 44291844)
24. Vaughn D, Muchmore D, Gee L, Ludington E. Dose response of recombinant human hyaluronidase effects on pharmacokinetics of regular human insulin and insulin lispro following SC injection [abstract]. Proceedings from the Biennial Congress of the International Diabetes Federation; 2009 Oct 18-22; Montreal, QC, Canada.
25. Vaughn D, Gee L, Ludington E, Muchmore D. Improved dose proportionality of insulin lispro injected with hyaluronidase. Proceedings from the Diabetes Technology Society Meeting; 2009 Nov 5-7; San Francisco, CA.
26. Muchmore D, Morrow L, Ludington E, Vaughn D, Hompesch M. Reduced variability of insulin lispro injected with hyaluronidase. Proceedings from the Diabetes Technology Society Meeting; 2009 Nov 5-7; San Francisco, CA.
27. Hompesch M, Muchmore D, Morrow L, Mongiovi D, Vaughn D. Accelerated insulin pharmacokinetics and improved glycemic control in T1DM patients by coadministration of prandial insulin with recombinant human hyaluronidase [abstract]. Annual Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans, LA.
28. Brunner GA, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Balent B, Schaupp L, Krejs GJ, Pieber TR. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus. Diabet Med. 2000;17(5):371-5. (Pubitemid 30353802)
29. Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care. 2006;29(8):1812-7. (Pubitemid 44156635)
30. Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; 2009.
31. Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000;37(1):41-6.
32. Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, Squatrito S, Furneri S, Marra G, Vitali L, Previti M, Cucinotta D. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabet Med. 2005;22(5):606-11. (Pubitemid 40593137)
33. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22(5):801-5. (Pubitemid 29220783)
34. Ramchandani N, Cantey-Kiser JM, Alter CA, Brink SJ, Yeager SD, Tamborlane WV, Chipkin SR. Self-reported factors that affect glycemic control in college students with type 1 diabetes. Diabetes Educ. 2000;26(4):656-66.
35. Chain E, Duthie ES. Identity of hyaluronidase and spreading factor. Br J Exp Pathol. 1940;21:324-38.
36. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427-40. (Pubitemid 47249140)
37. Wiefels K, Kuglin B, Hubinger A, Jorgensen LN, Gries FA. Insulin kinetics and dynamics in insulin-dependent diabetic patients after injections of human insulin or the insulin analogues X14 and X14 + Zn. In: Berger M, Gries FA, editors. Frontiers in insulin pharmacology. New York: Thieme Medical Publishers, Inc.; 1993. p. 97-101.
38. Burket LC, Gyorgy P. Clinical observations on the use of hyaluronidase. Pediatrics. 1949;3(1):56-63.
39. Schwartzman J. Hyaluronidase; a review of its therapeutic use in pediatrics. J Pediatr. 1951;39(4):491-502.
40. Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med. 2007;10(6):1312-20. (Pubitemid 350308641)
41. Remy M, Pinter F, Nentwich MM, Kampik A, Schonfeld CL. Efficacy and safety of hyaluronidase 75 IU as an adjuvant to mepivacaine for retrobulbar anesthesia in cataract surgery. J Cataract Refract Surg. 2008;34(11):1966-9.
42. Khandwala M, Ahmed S, Goel S, Simmons IG, McLure HA. The effect of hyaluronidase on ultrasound-measured dispersal of local anaesthetic following sub-Tenon injection. Eye. 2008;22(8):1065-8.
43. Forbes GB, Deisher RW. Effect of hyaluronidase on the subcutaneous absorption of electrolytes in humans. Science. 1950;111(2877):177-9.
44. Lipschitz S, Campbell AJ, Roberts MS, Wanwimolruk S, McQueen EG, McQueen M, Firth LA. Subcutaneous fluid administration in elderly subjects: validation of an under-used technique. J Am Geriatr Soc. 1991;39(1):6-9.
45. Thomas JR, Wallace MS, Yocum RC, Vaughn DE, Haller MF, Flament J. The INFUSE morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage. 2009;38(5):663-72.
46. Thomas JR, Yocum RC, Haller MF, Flament J. The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers. J Pain Symptom Manage. 2009;38(5):673-82.
47. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infus Nurs. 2007;30(5):293-9. (Pubitemid 47585290)
48. Søeborg T, Rasmussen CH, Mosekilde E, Colding-Jorgensen M. Absorption kinetics of insulin after subcutaneous administration. Eur J Pharm Sci. 2009;36(1):78-90.
49. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990;7(2):167-9. (Pubitemid 20208069)
50. Data on file. San Diego, CA: Halozyme Therapeutics; 2009.